If you want to build a career in biotech, should you get a PhD after college or join a company directly (as a Research Associate/RA, usually)?
There's no single answer, but I have the conversation often enough that I thought I'd share some pros/cons... (1/n)
First, see this thread about different types of biopharma companies. For reasons I'll get into, I think early stage (probably founder led) biotech is your best bet unless you still want to do PhD later.
(PS if you want to be a professor, it's 💯 PhD) 2/n
PhD will give you more options.
Some companies (incl. @GordianBio) will help you grow from RA to Scientist role (and beyond). But many, esp larger, companies have a glass ceiling if you don't have a PhD. Even if you pick one w/o glass ceiling, you'll be worse off it if fails. 3/n
But a wetlab PhD takes 5-7 years. A good and driven RA could (in right co, with supportive mentor) make Scientist in 3-4. So there's real opportunity cost.
Your salary will also be 2-3x, although at this career stage you should focus on learning > earning if you can. 4/n
(And of course, if you manage to join an extraordinary company the opportunity cost of ~3y is huge. You might end up joining as employee #30 instead of #10, with meaningful differences in equity, learning, and network-building). 5/n
What will you learn? Varies a lot, but PhD should teach 1) experimental design, 2) science communication, 3) the foundations and implicit knowledge of a field, and ideally 4) new skills that very few possess.
RA hopefully 1+2, 3 might need more self-study, and 4 not always. 6/n
OTOH RA can teach you (by exposure) more about how companies work: working within a team, organization coordination, urgency, a higher bar for reproducibility, drug development strategy, and more. These skills are less unique, but more widely applicable. 7/n
(And some of those unique skills turn out to be in little demand, e.g. if you become the leading expert on the reproductive system of roundworms) 8/n
Both can offer smart colleagues, interesting science, and service to humanity.
PhD gives you more independence earlier, RA gives you resources and a sense of urgency earlier. Academia might make you feel like you're in a Kafka story, RA might make you feel like a robot. 9/n
As I said, no clear answer!
If you're very sure about biotech > academia, and you think you've found an exceptional company that will support you, RA could give you the fastest progress. But many RA positions could be a dead end, or at best prep for doing a PhD anyway. 10/n
Should also mention, in either case a LOT of your experience depends on whether your mentor is smart and supportive. Without that you'll be hamstrung and frustrated. Pick the good mentor over other factors 99% of the time. 11/11
This thread is more popular than the one on understanding aging, y'all need to reconsider your priorities 😂

I do know cos hiring RAs (mostly in SF) so any bio grads who decide on that path can email my first name at gordian.bio w your interests and I'll redirect.
Also know people looking for PhD students (in #aging/#longevity at least), but you'll need to apply for the programs first etc. so probably not helpful...

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Martin Borch Jensen

Martin Borch Jensen Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @MartinBJensen

Jul 3
All these points resonate, for early stage biotech at least. @erlichya touches on this, but I think worth separating "industry" into different clusters that will feel quite different to someone coming from academia (still oversimplified, of course):
Pharma (eg Pfizer) vs biotech:
You wear fewer hats, see less of the company but company as a whole spans wider range of expertise, fewer changes in direction, often higher income but no chance of getting rich. Both have job insecurity: pharma doesn't go die but programs do.
Clinical vs R&D stage biotech:
Clinical may still have R&D but it's no longer the biggest driver of success vs failure. Assay validation/rigor > assay development/invention. Clinical can feel more like pharma, but with more urgency/stakes: one program = life or death of co.
Read 7 tweets
Jan 24
#SciTwitter After a lot of research and asking around, I'm making the lab equipment recommendations 🧵 I wish I'd had 2 months ago. RT/share with a #newPI or startup 🔬⚗️🛒
Note, much of the equipment hasn't arrived yet, will add comments after actual use.
-80 #freezer
Two clear winners: PHC (@panasonic) and Stirling Ultracold. Both low energy, quiet, reliable. We went with PHC because I know those to last many years, and slightly cheaper.
Thanks @MarcoJost_ @letUbeU @aryelipman #MBCBiolabs
-20 #freezer
Less clear, many viable options. We ended up getting a split of PHC MDF -30 (recommended as quieter) and much cheaper Corepoint Scientific/@VWR, will see which we prefer. Thermo hasn't failed #MBCbiolabs, but $$$ and several people said poor customer support.
Read 14 tweets
Jan 5
Something is changing about how scientific research is funded.

@Jasonmmast @endpts covers a growing set of science funding experiments: endpts.com/inside-the-mul…
These include high-throughput grants (e.g. #Fast, #Impetus), new institutes (@ArcadiaScience, @AltosLabs, @arcinstitute... I guess A is for new beginnings?), and new structures like 'nonprofit startups' (@Convergent_FROs) & @newscienceorg.
As with all experiments, I expect that some of these will disappear and that others will be a central part of science in ten years.
But them happening at all is enough to renew a conversation about how science is funded and conducted.
Read 9 tweets
Dec 27, 2021
💸 98 Longevity Impetus Grants were awarded in 2021, thanks to generous donations from @juanbenet @jamesfickel @VitalikButerin @JedMcCaleb @KarlPfleger @FEhrsam and 1 anonymous donor.
I'll summarize outcomes in this thread, awardees listed in prior one:
🦸🏽 While I've been doing most of the tweeting, the Longevity Apprentices @LNuzhna @kush__sharma @edmarferreira & Tara Mei are the real heroes for running the operations.
This has been a great Apprenticeship project, merging action and exposure to research
martinborchjensen.com/apprenticeship
🚅 The review + awards process was fairly smooth, thanks in part to @kush__sharma's custom reviewer UI. Several reviewers told us unprompted that it was their best review experience ever; the UI took 2 wks to make, so there's low hanging fruit for other agencies in that area.
Read 13 tweets
Sep 7, 2021
Thrilled to announce the Longevity #Impetus Grants, $21M+ towards basic research that could accelerate our understanding and control of human aging.
We welcome proposals from researchers in- and outside the #Aging field. Please share!

More info: impetusgrants.com & this 🧵
Impetus Grants are $10k-500k (w max 10% overhead). Smaller requests favored, to support more projects. No project period and no strings attached. Scientists at non-profits worldwide can apply with ideas that shift perspectives & capabilities in #Aging research, starting Sep 13th.
Inspiration came from @tylercowen & @patrickc's #COVID19 Fast Grants. Their team made funding decisions in 2 weeks, and the grants have already led to both discoveries and better tools for #testing.
If it's feasible to fund science this way, shouldn't we? future.a16z.com/what-we-learne…
Read 15 tweets
Jun 23, 2021
Arlan Richardson showing that JAX-housed mice, like humans, have undergone a dramatic improvement in #lifespan this century ... by reducing deaths from pathogens. #MindYourModels
Recommends looking at lifespan data as the best indicator of husbandry quality at different institutions/sources. Mean survival should be at least 27-30 months.
Example: 2003 Igf1r study showing 33% lifespan extension (in het ♀️s), but mean lifespan of controls was only 19mos. Lifespan effect largely disappeared when replicated in cohorts with longer control lifespan.
This was my go-to question for fly lifespan studies as a postdoc.
Read 7 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us on Twitter!

:(